Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells

Cardiovascular Research

Volumn 90, Issue 1, 2011, Pages 113-121

  Vallabhaneni, Krishna C ^a   Tkachuk, Sergey ^a   Kiyan, Yulia ^a   Shushakova, Nelli ^a,b   Haller, Hermann ^a   Dumler, Inna ^a   Eden, Gabriele ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Phenos GmbH   (Germany)

Author keywords

Cell differentiation; Cell migration; Cell mobilization; Mesenchymal stem cells; Urokinase receptor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL STRUCTURE; DOWN REGULATION; FEMORAL ARTERY; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STEM CELL MOBILIZATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SHAPE; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEK293 CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, CXCR4; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; VASCULAR SYSTEM INJURIES;

EID: 79952837741     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq362     Document Type: Article

References (50)

1. Ohishi M, Schipani E. Bone marrow mesenchymal stem cells. J Cell Biochem 2009;109: 277-282.
2. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20. (Pubitemid 38931831)
3. Abedin M, Tintut Y, Demer LL. Mesenchymal stem cells and the artery wall. Circ Res 2004;95:671-676. (Pubitemid 39331926)
4. Huang NF, Li S. Mesenchymal stem cells for vascular regeneration. Regen Med 2008;3: 877-892.
5. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97:336-342. (Pubitemid 46437793)
6. Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR, Masucci MT et al. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 1990; 32:247-253.
7. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nature Rev Mol Cell Biol 2002;3:932-943. (Pubitemid 35477371)
8. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic cell mobilization. Blood 2005;105:198-205.
9. Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV et al. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res 2006;66:10885-10890. (Pubitemid 44876986)
10. Tjwa M, Sidenius N, Moura R, Jansen S, Theunissen K, Andolfo A et al. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J Clin Invest 2009;119:1008-1018.
11. Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park JK, Hashimoto K et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Science 2005;118:2743-2753. (Pubitemid 40932898)
12. Tkachuk N, Kiyan J, Tkachuk S, Kiyan R, Shushakova N, Haller H et al. Urokinase induces survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic stimulus. Biochem J 2008;415:265-273.
13. Shi Q, Hodara V, Butler SD, Thomas CA, Hubbard GB, VandeBerg JL et al. Differential bone marrow stem cell mobilization by G-CSF injection or arterial ligation in baboons. J Cell Mol Med 2009;13:1896-1906.
14. Cheng Z, Liu X, Ou L, Zhou X, Liu Y, Jia X et al. Mobilization of mesenchymal stem cells by granulocyte colony-stimulating factor in rats with acute myocardial infarction. Cardiovasc Drugs Ther 2008;22:363-371.
15. Hegner B, Weber M, Dragun D, Schulze-Lohoff E. Differential regulation of smooth muscle markers in human bone marrow-derived mesenchymal stem cells. J Hypertens 2005;23:1191-1202. (Pubitemid 40862723)
16. Chen J, Park HC, Addabbo F, Ni J, Pelger E, Li H et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kindey Int 2008;74:879-879.
17. Kim YM, Jeon ES, Kim MR, Jho SK, Ryu SW, Kim JH. Angiotensin II-induced differentiation of adipose tissue-derived mesenchymal stem cells to smooth muscle-like cells. Int J Biochem Cell Biol 2008;40:2482-2491.
18. Ross JJ, Hong Z, Willenbring B, Zeng L, Isenberg B, Lee EH et al. Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest 2006;116:3139-3149. (Pubitemid 44878628)
19. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fisher M, Olson M, Rinon A. et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008;3:e3707.
20. Tamama K, Sen CK,Wells A. Differentiation of bone marrow mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAPK signaling pathway. Stem Cells Dev 2008;17:897-908.
21. Gong Z, Calkins G, Cheng EC, Krause D, Niklason LE. Influence of culture medium on smooth muscle cell differentiation from human bone marrow-derived mesenchymal stem cells. Tissue Eng Part A 2009;15:319-330.
22. Bonfield TL, Caplan AI. Adult mesenchymal stem cells: an innovative therapeutic for lung diseases. Discov Med 2010;9:337-345.
23. Wang CH, Cherng WJ, Yang NI, Kuo LT, Hsu CM, Yeh HI et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2008;28:54-60.
24. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J. et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436. (Pubitemid 32298545)
25. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111: 150-156. (Pubitemid 40139725)
26. Kashiwakura Y, Katoh Y, Tamayose K, Konishi H, Takaya N, Yuhara S et al. Isolation of bone marrow stromal cell-derived smooth muscle cells by a human SM22alpha promoter: in vitro differentiation of putative smooth muscle progenitor cells of bone marrow. Circulation 2003;107:2078-2081. (Pubitemid 36532186)
27. Zuk PA, Zhu M, Mizuno H, Huang J, Fitrell JW, Katz AJ et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng Part A 2001;7: 211-228. (Pubitemid 32295155)
28. Matsumura G, Miyagawa-Tomita S, Shin'oka T, Ikada Y, Kurosawa H. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation 2003;108:1729-1734. (Pubitemid 37243662)
29. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368. (Pubitemid 40562318)
30. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95. (Pubitemid 38813459)
31. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104:3581-3587. (Pubitemid 39564430)
32. Steins MB, Padro T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 2004;15:383-391. (Pubitemid 38901608)
33. Salame MY, Samani NJ, Masood I, deBono DP. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000;152:19-28.
34. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997;811:191-206. (Pubitemid 27308328)
35. Okada SS, Golden MA, Raghunath PN, Tomaszewski JE, David ML, Kuo A et al. Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. Thromb Haemost 1998;80:140-147. (Pubitemid 28353512)
36. Roelofs JJTH, Rowshani AT, Van den Berg JG, Claessen N, Aten J, Ten Berge IJM et al. Expresssion of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kindey Int 2003;64:1845-1853. (Pubitemid 37323716)
37. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004;25:450-455. (Pubitemid 38951087)
38. Mazzieri R, Blasi F. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost 2005;93:641-646. (Pubitemid 40485398)
39. Bernstein AM, Twining SS, Warejcka DJ, Tall E, Masur SK. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Biol Cell 2007; 18:2716-2727. (Pubitemid 47025736)
40. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelialmesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178:425-436. (Pubitemid 47196151)
41. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009;284:22825-22833.
42. Kiyan J, Kusch A, Tkachuk S, Kramer J, Dietz R, Smith G et al. Urokinase receptor and RhoA mediate non-lipid lowering effects of rosuvastatin on vascular remodeling. Atheriosclerosis 2007;195:254-261.
43. Kiyan J, Smith G, Haller H, Dumler I. Urokinase receptor-mediated phenotypic changes of vascular smooth muscle cells require involvement of membrane rafts. Biochem J. 2009;423:343-351.
44. Bonnet P, Awede B, Rochefort GY, Mirza A, Lermusiaux P, Domenech J et al. Electrophysiological maturation of rat mesenchymal stem cells after induction of vascular smooth muscle cell differentiation in vitro. Stem Cells Dev 2008;17:1131-1140.
45. Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008;26:1406-1413.
46. Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA et al. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 2008;6:1819-1829.
47. Kusch A, Tkachuk S, Haller H, Dietz R, Gulba DC, Lipp M et al. Urokinase-dependent activation of phosphatidylinositol 3-kinase: intercation with Tyk2 and requirement for human vascular smooth muscle cell migration. J Biol Chem 2000;275:39466-39473. (Pubitemid 32058972)
48. Kiyan Y, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells are mediated by PDGFR-ß. EMBO J 2005;24:1787-1797. (Pubitemid 40769498)
49. Kiian I, Tkachuk N, Haller H, Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost 2003;89:904-914. (Pubitemid 36603434)
50. Fritz V, Noël D, Bouquet C, Opolon P, Voide R, Apparailly F et al. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 2008;26:2981-2990.